Recruiting

Observational Study

Sponsor:

Gilles Boire

Code:

NCT00512343

Conditions

Arthritis

Eligibility Criteria

Sex: All

Age: 3 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The objectives of this group project is to collect synovial fluid (SF) and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

Conditions

Arthritis

Study ID

NCT00512343

Start date

Jun, 2002

Status verified date

May, 2026

Completion date

Sep, 2030

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 3 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Significant joint effusion

Exclusion Criteria:

  • Hemorrhagic effusion
  • Traumatic effusion
  • Less than 3 ml total of collected fluid (used for routine analysis and culture)
  • Inability or refusal to consent

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Availability of paired synovial fluid and serum samples for exploratory studies [ Time Frame: Use with various collaborators at different times, upon request and approbation ]

Central Contacts and Locations

Central contacts

Gilles Boire, MD, MSc

(819) 564-5261Gilles.Boire@USherbrooke.ca

Locations

Centre hospitalier universitaire de Sherbrooke

Recruiting

Sherbrooke, Quebec, Canada, J1H 5N4

Contacts

Gilles Boire, MD, MSc

(819) 564-5261Gilles.Boire@USherbrooke.ca

Principal Investigator:

Gilles Boire, MD, MSc

More Information

Sponsor

Gilles Boire

Last update posted

May 15, 2026

Last verified

May, 2026

Keywords

  • Synovial Fluid
  • Arthritis
  • Paired serum/synovial fluid samples

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Gilles Boire on 2026-05-15.